Fat Accumulation Inhibitor from V. fauriei
1235
8) Henry DY, Gueritte-Voegelein F, Insel PA, Ferry N, Bouguet J,
Potier P, Sevenet T, and Hanoune J, Eur. J. Biochem., 170, 389–
394 (1987).
cellular signaling mediated by G2A has not been fully
elucidated. It is possible that the cytokines released by
G2A played a role in the inhibition of fat accumulation
after 9-HODE bound to G2A.
We successfully isolated 9-HODE in this study as an
inhibitor of fat accumulation and found that 13-HODE
had the same effect. The hydroxylated derivatives of
conjugated linoleic acid may be potent inhibitors of
fat accumulation, making it important to evaluate the
activity of other analogs of 9-HODE.
9) Li Z, Tran VH, Duke RK, Ng MCH, Yang D, and Duke CC,
Chem. Phys. Lipids, 158, 39–45 (2009).
10) Hubke H, Garbe L-A, and Tressl R, Agric. Food Chem., 53,
¨
1556–1562 (2005).
11) Hara K, ‘‘Kyoyakurinorusannoseikagakutoouyou’’ (in Japanese),
Saiwai Shobo, Tokyo, pp. 14–144 (2000).
12) Schild RL, Schaiff WT, Carlson MG, Cronbach EJ, Nelson DM,
and Sadovsky Y, J. Clin. Endocrinol. Metab., 87, 1105–1110
(2002).
13) Obinata H, Hattori T, Nakane S, Tatei K, and Izumi T, J. Biol.
Chem., 280, 40676–40683 (2005).
Experimental
General data. 1H-NMR spectra were recorded with a JeolL JNM
AL300 FT NMR spectrometer. 9-HODE (3). 1H-NMR (300 MHz,
CDCl3) ꢂ: 0.89 (3H, t, J ¼ 6:8), 1.21–1.59 (18H, m), 2.18 (2H, m),
2.35 (2H, t, J ¼ 7:5), 4.15 (1H, m), 5.44 (1H, m), 5.66 (1H, dd,
J ¼ 6:8, 15.2), 5.97 (1H, dd, J ¼ 11:2, 11.2), 6.49 (1H, dd, J ¼ 11:2,
15.2).
14) Ogawa A, Obinata H, Hattori T, Kishi M, Tatei K, Ishikawa O,
and Izumi T, J. Pharmacol. Exp. Ther., 332, 469–478 (2010).
15) Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T,
Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K,
Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa
G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T,
Fujita T, Ezaki O, Aizawa S, Nagai R, Tobe K, Kimura S, and
Kadowaki T, Mol. Cell, 4, 597–609 (1999).
References
16) Yamauchi T, Waki H, Kamon J, Murakami K, Motojima K,
Komeda K, Miki H, Kubota N, Terauchi Y, Tsuchida A,
Kasaoka N, Yamauchi N, Ide T, Hori W, Kato S, Fukayama M,
Akanuma Y, Ezaki O, Itai A, Nagai R, Kimura S, Tobe K,
Kagechika H, Shudo K, and Kadowaki T, J. Clin. Invest., 108,
1001–1013 (2001).
1) Mann CC, Science, 307, 1716–1717 (2005).
2) Shimokawa K, Mashima I, Asai A, Yamada K, Kita M, and
Uemura D, Tetrahedron Lett., 47, 4445–4448 (2006).
3) Shimokawa K, Yamada K, Kita M, and Uemura D, Bioorg.
Med. Chem. Lett., 17, 4447–4449 (2007).
4) Ito M, Ito J, Kitazawa H, Shimamura K, Fukami T, Tokita S,
Shimokawa K, Yamada K, Kanatani A, and Uemura D,
Peptides, 30, 1074–1081 (2009).
17) Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H,
Hagura R, Akanuma Y, Kimura S, Ito C, and Kadowaki T,
Biochem. Biophys. Res. Commun., 271, 212–216 (2000).
18) Kamon J, Yamauchi T, Terauchi Y, Kubota N, and Kadowaki T,
Folia Pharmacol. Jpn., 122, 294–300 (2003).
5) Sashida Y and Yamasaki K, ‘‘Syouyakugaku’’ (in Japanese),
Nankodo, Tokyo, pp. 258–260 (1997).
6) Konoshima M, Sawada T, and Hata K, ‘‘Syouyakugaku’’ (in
Japanese), Asakura Publishing, Tokyo, pp. 234–236 (1978).
7) Guo Y, Xu J, Li Y, Watanabe R, Oshima Y, Yamakuni T, and
Ohizumi Y, Chem. Pharm. Bull., 54, 123–125 (2006).
19) Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K,
Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y,
and Kadowaki T, J. Clin. Invest., 101, 1354–1361 (1998).